Similar Search Results

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland

Lebioda, Andrea; Gasche, David; Dippel, Franz-Werner; … - In: Health Economics Review 4 (2014) 1, pp. 1-14

Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …

Persistent link: https://www.econbiz.de/10011151927

The German approach to cost-effectiveness analysis in health care

Hevér, Noémi V.; Balogh, Orsolya - In: Society and Economy 35 (2013) December, pp. 551-572

of Health Technology Assessment (DAHTA) and the Institute for Quality and Efficiency in Health Care (IQWiG). The … operational principles of IQWiG are somewhat different from the rules governing HTA organizations in other countries. The … such benefits, but in 2010, cost-effectiveness analysis was introduced as an integral part of the HTA process at IQWiG. A …

Persistent link: https://www.econbiz.de/10010720271

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation

Ruof, Jörg; Schwartz, Friedrich; Schulenburg, J.-Matthias - In: The European Journal of Health Economics 15 (2014) 6, pp. 577-589

Considerable variance was observed in the levels of additional benefit reported by pharmaceutical manufacturers, IQWiG …

Persistent link: https://www.econbiz.de/10010993901

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany

Dabisch, Inna; Dethling, Jürgen; Dintsios, … - In: Health Economics Review 4 (2014) 1, pp. 1-8

D61; H51; I18. </AbstractSection> Copyright Dabisch et al.; licensee Springer. 2014

Persistent link: https://www.econbiz.de/10010998823

Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products

Schwander, Björn; Banz, Kurt; Kaier, Klaus; Walzer, Stefan - In: Health Policy 117 (2014) 3, pp. 334-344

products (AMNOG). Since then the normal procedure for reimbursement of a new pharmaceutical is a benefit assessment by the …

Persistent link: https://www.econbiz.de/10011048307

Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation

Henschke, Cornelia; Sundmacher, Leonie; Busse, Reinhard - In: Health Policy 109 (2013) 3, pp. 263-269

spending, the Act for Restructuring the Pharmaceutical Market in Statutory Health Insurance (AMNOG) came into effect on 1st …

Persistent link: https://www.econbiz.de/10011048324